CurrentUnitedHealthcarePolicy CSOH2025D0048.C

Intravenous Enzyme Replacement Therapy (ERT) for Gaucher Disease (Ohio only)

This policy governs medical benefit coverage and medical necessity determination for intravenous ERT drugs used to treat Gaucher disease for UnitedHealthcare members in Ohio.

Policy Summary

PayerUnitedHealthcare

PolicyIntravenous Enzyme Replacement Therapy (ERT) for Gaucher Disease (Ohio only)

Policy CodePolicy CSOH2025D0048.C

Change TypeRoutine reviewno content changes

Effective DateAug 1, 2025

Next Review DateN/A

Key ActionObtain prior authorization that meets the current InterQual Specialty Rx Non-Oncology criteria for the selected ERT and reference HCPCS codes J1786, J3060, or J3385.

SourceLink

POLICY UPDATE CHANGES

Routine review; no content changes.

3intravenous ERT products referenced

OHstate-specific applicability

J1786, J3060, J3385HCPCS/J-codes listed

InterQualutilizes InterQual clinical criteria

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial and ongoing medical necessity

Covered when ALL of the following are met per the current InterQual specialty criteria:

InterQual-based coverage: Member meets the current InterQual CP: Specialty Rx Non-Oncology criteria for the specific ERT (imiglucerase for Cerezyme, taliglucerase alfa for Elelyso, velaglucerase alfa for VPRIV)per InterQual

Refer to the current InterQual release for detailed clinical eligibility and required documentation

This policy applies only to UnitedHealthcare members in Ohio (OH). When determining coverage, providers must reference applicable federal, state (Ohio Administrative Code [OAC]), or contractual requirements because those terms may differ from the standard benefit plan and, in the event of a conflict, federal, state (OAC), or contractual requirements will govern.

Services that are stated as unproven or those subject to coverage or quantity limits will be evaluated for medical necessity using OAC 5160-1-01. This Medical Benefit Drug Policy is informational and should be used alongside the applicable plan contract and regulatory requirements.

This document underwent a routine review on 08/01/2025. No content changes were made in this review; the previous policy version CSOH2024D0048.B was archived.

Provider Actions and Prior Authorization

Prior Authorization

Prior Authorization Required

Coverage requires meeting the current InterQual Specialty Rx Non‑Oncology clinical criteria for each drug. Prior authorization is required for Cerezyme (imiglucerase), Elelyso (taliglucerase alfa), and VPRIV (velaglucerase alfa); approvals will be granted only when the member’s clinical situation meets the applicable InterQual criteria referenced in this policy.

Applies to J1786 (imiglucerase), J3060 (taliglucerase alfa), J3385 (velaglucerase alfa).
Prior authorization must reference current InterQual criteria release and specific drug criteria set.

Documentation Required

Required Documentation

Providers must submit documentation supporting medical necessity with the prior authorization request. Documentation should include relevant clinical information, prior treatment history, diagnostic test results, and any specialty-specific assessments required by the InterQual criteria.

Include member diagnosis, relevant laboratory or imaging results, treatment start and stop dates, prior enzyme replacement therapies and responses, and rationale for agent selection.
If applicable, include documentation to demonstrate that any plan or state-mandated step therapy or limits have been addressed.

Denial Risk

Denial Triggers and Risk

Requests that do not meet the current InterQual clinical criteria, are for services considered experimental/unproven, or exceed contract or benefit limits are subject to denial. Providers should verify benefit plan terms and applicable federal or state mandates before submitting requests to reduce denial risk.

Denial may occur if InterQual criteria not met.
Denial may occur for services considered investigational or not supported by clinical evidence.
Denial may occur when request exceeds plan-specific limits or lacks required documentation.

Background

Gaucher disease is managed with intravenous enzyme replacement therapy (ERT) to replace deficient glucocerebrosidase enzyme activity. This policy references three FDA‑approved IV ERT products — imiglucerase (Cerezyme), taliglucerase alfa (Elelyso), and velaglucerase alfa (VPRIV) — and relies on the current InterQual Specialty Rx Non‑Oncology criteria to determine clinical eligibility, initiation, and continuation of therapy.

Intravenous ERT is indicated to treat the systemic manifestations of Type 1 Gaucher disease; coverage decisions for initiation and ongoing treatment are made by determining whether the member meets the applicable InterQual criteria for the specific ERT product.

Definitions

ERT: Intravenous enzyme replacement therapy

DefinitionIntravenous enzyme replacement therapy (ERT): administration of recombinant glucocerebrosidase (e.g., imiglucerase, taliglucerase alfa, velaglucerase alfa) to replace deficient enzyme activity and treat manifestations of Gaucher disease.

Examples (referenced products)Cerezyme (imiglucerase); Elelyso (taliglucerase alfa); VPRIV (velaglucerase alfa)

Indication contextUsed for treatment of Type 1 Gaucher disease when medical necessity criteria in the current InterQual Specialty Rx Non-Oncology criteria are met.

Clinical criteria sourceCoverage and continued use are determined per the current release of the applicable InterQual CP: Specialty Rx Non-Oncology for each ERT product.

Initial Therapy Criteria

Initial therapy

Initial coverage requires meeting the current InterQual Specialty Rx Non-Oncology criteria for the selected drug.

Initial therapy: Member meets InterQual initial eligibility criteria for the selected ERTper InterQual

See InterQual CP for drug-specific entry criteria (Imiglucerase, Taliglucerase alfa, Velaglucerase alfa)

Continuation Therapy Criteria

Continuation therapy

Continuation coverage is subject to ongoing meeting of the InterQual criteria for the specific ERT product.

Continuation: Ongoing therapy is covered when the member continues to meet InterQual continuation criteria for the specific ERTper InterQual

Refer to InterQual for monitoring, response, and renewal requirements

Site of Care

Step Therapy

Follow federal/state/contractual rules for infusion site‑of‑care

Site‑of‑care and infusion center determinations must follow applicable federal, state (OAC), or contractual requirements and payer policies; this policy provides informational guidance only and does not override governing coverage terms.

Confirm whether federal, state, or contractual rules dictate the allowed administration setting prior to scheduling or billing.
Follow payer site‑of‑care policies in conjunction with InterQual clinical determinations.